Navigation Links
Genentech/Roche/Chugai's Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
Date:10/21/2008

Significant Unmet Need Remains for Agents that are Effective in Treating Triple-Negative Beast Cancer, According to a New Report from Decision Resources

WALTHAM, Mass., Oct. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that significant market penetration will drive Genentech/Roche/Chugai's Avastin to garner just over 20 percent of total sales in the breast cancer drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan in 2017.

The new Pharmacor report entitled Breast Cancer finds that, through 2017, the breast cancer drug market will be driven by sales of Avastin in the U.S. and Europe, its approval and launch in Japan, and its label extension to the adjuvant setting in 2013. Additionally, although Genentech/Roche/Chugai's Herceptin continues to dominate the human epidermal growth factor receptor-2 (HER2) positive breast cancer market segment, the drug is receiving strong competition from GlaxoSmithKline's Tykerb, which has received favorable physician opinion. However, Tykerb's premium price continues to limit its potential uptake, according to the report.

Market growth will also be driven by the entry of Pfizer's Sutent, currently in clinical trials, which is expected to be approved for the treatment of advanced breast cancer in 2010. Sutent's subsequent approval in the adjuvant setting between 2012 and 2017 will further drive its robust growth. Interviewed experts said they are strongly encouraged by Sutent's clinical trial data to date and express confidence in the drug's potential in breast cancer and are particularly hopeful of its potential in the treatment of triple-negative breast cancer. Triple-negative breast tumors--which account for approximately one-fifth of all breast cancers--are defined by their lack of expression of estrogen, progesterone and HER2 receptors.

"Lack of receptor expression results in resistance to conventional hormonal and targeted therapies, leaving chemotherapy as the only treatment option for patients with triple-negative breast cancer," said Niamh Murphy, Ph.D., analyst at Decision Resources. "As a result, there is a significant unmet need for the development of effective agents for the treatment of triple-negative breast cancer."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Decision Resources Decision Resources, Inc.

Christopher Comfort Elizabeth Marshall

781-296-2597 781-296-2563

ccomfort@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
2. Avastin Added to Chemo Helps Women With Advanced Cancer
3. Off-Label Avastin Use for Wet Macular Degeneration
4. FDA OKs Avastin for Advanced Breast Cancer
5. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
6. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
7. Many More Patients Can Now Benefit from Avastins Proven Survival Benefits
8. Taxol with avastin produces noteworthy results
9. FDA Panel Says No to Avastin for Advanced Breast Cancer
10. Rising Garners Top Honors on the Private Company Indexs Top Five Growth Companies List for Q1 2008
11. Study garners unique mating photos of wild gorillas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... ... and clinical practice of radiosurgery, is recognizing five medical residents and students for ... stereotactic body radiotherapy (SBRT). The awards will be presented at the 2016 SRS/SBRT ...
(Date:5/24/2016)... ... 24, 2016 , ... Bio-Logic Aqua® Research Water Life Science® ... a trainer for Ageless Grace ( http://www.agelessgrace.com ) to discuss healthier lifestyles, especially ... 2016. , Formerly a Northwestern University Literature Professor, Kinst gravitated to her career ...
(Date:5/24/2016)... ... May 24, 2016 , ... In light of recent ... of the potential of contaminated well water throughout the Houston area. , Heavy floodwaters ... well water that’s exposed to contaminants. Residents may not even be aware of the ...
(Date:5/24/2016)... ... 2016 , ... The Dream Builders Project, a 501(c)3 nonprofit organization based in ... in Tijuana, Mexico on Saturday, May 21st. The volunteers took the children out for ... More than 15 volunteers traveled from Los Angeles to Tijuana, Mexico for the day ...
(Date:5/24/2016)... Greenwich, Connecticut (PRWEB) , ... May 24, 2016 ... ... of Lyme and tick-borne disease research and education, today announced that it has ... and CEO of the Bonnie J. Addario Lung Cancer Foundation (ALCF) in San ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... , May 23, 2016 Diplomat Pharmacy, Inc. (NYSE: ... Fellowship and Internship programs. The hands-on learning experience is ... The full-time, paid Fellowship and Internship ... . Fellows and interns are provided optional housing ... Flint at the Riverfront Residence Hall to ...
(Date:5/23/2016)... The World Health Organization (WHO) expanded the Intended ... adolescents aged 13 years, and above. Effective immediately, the PrePex ... and adolescent males in the 14 priority countries in Southern ... first male circumcision device to receive WHO Prequalification on 31 ... said: " The expanded use of PrePex ...
(Date:5/23/2016)... 2016 The global  reprocessed medical ... by 2022, according to a new study by Grand ... coupled with the lack of centralized support for waste ... the demand for reprocessed medical devices market. Additionally, the ... that of the original device is the high impact ...
Breaking Medicine Technology: